Home › Companies › IMVT

Immunovant

Market cap $6.87B 206.9M shares (10-Q, Nov 3, 2026) × $33.21 close Nov 17, 2026

Most recent annual filing: 2026-05-20

Pipeline (4 active programs)

Discontinued (3)

Capital (as filed)

Cash
$722M cash and cash equivalents · Sep 30, 2026 (10-Q)
Operating cash flow
−$83.2M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$722M cash per the update of Nov 9, 2026 — the company's own words as read there, not the filed figure

Offering documents (1)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (7)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (7 calls)

Every verdict Biotech Distilled has published on Immunovant, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Buy core Immunovant (IMVT): Scientific Deep Dive for IMVT-1402 and Pipeline Products IMVT-1402's engineered fix for batoclimab's albumin/LDL safety flaws creates an asymmetric entry point despite HanAll legal risk, with strong Phase 1 data and a billion-dollar cash runway.
  2. Buy core UPDATE: Immunovant (IMVT) - Quarterly Update Q3 earnings confirm the thesis is intact: $1B cash fortress removes dilution risk, all six IMVT-1402 trials enrolling on schedule, and HanAll legal situation remains stable.
  3. Buy core UPDATE: Immunovant (IMVT) - The Bato Swan Song and the Pivot to Purity Batoclimab's Phase 3 TED data validated the anti-FcRn mechanism while confirming the lipid safety flaw, clearing the deck for IMVT-1402 and creating a buying opportunity if the market misreads the mixed headlines as a company failure.
  4. Buy core UPDATE: Immunovant (IMVT) - The Bio-Better Bet Cashes Its First Check IMVT-1402's first efficacy data in sick patients showed clean safety and strong ACR response rates, partially de-risking the bear case, though the stock is less attractively priced and HanAll posture hardened to pre-litigation.
  5. Buy core UPDATE: Immunovant (IMVT) - The Quarter Where the Burn Got Real No new data or timeline slips across six trials, HanAll escalation paused for a full quarter, but burn accelerated to $124M/quarter and management flagged potential unbudgeted late-stage expansion, making the dilution gap data-contingent rather than nonexistent.
  6. Hold UPDATE: Immunovant (IMVT) - The First Placebo Test Comes Back Empty IMVT-1402 missed its primary endpoint in CLE — the first blinded placebo-controlled test — concentrating all near-term binary risk on D2T RA Period 2, making this a wait-for-the-placebo-print moment rather than a buy-the-dip one.
  7. Buy core UPDATE: Immunovant (IMVT) - The Placebo Test, Passed (With Footnotes) IMVT-1402 600mg beat placebo in the D2T RA withdrawal test and the failed 300mg arm validates the depth thesis for Graves' disease, repairing the dented thesis and making this a reasonable point to rebuild a Graves'-driven position.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Filings & releases (17)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Jul 23, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

2 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)